Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 998.00
-2.00 (-0.20%)
Sep 22, 2026, 3:30 PM KST
Xcell Therapeutics Revenue
Xcell Therapeutics had revenue of 1.94B KRW in the quarter ending June 30, 2026, with 775.44% growth. This brings the company's revenue in the last twelve months to 4.36B, up 193.30% year-over-year. In the year 2025, Xcell Therapeutics had annual revenue of 1.95B with 0.76% growth.
Revenue (ttm)
4.36B
Revenue Growth
+193.30%
P/S Ratio
3.96
Revenue / Employee
n/a
Employees
n/a
Market Cap
17.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | 14.65M | 0.76% |
| Dec 31, 2024 | 1.93B | 810.45M | 72.11% |
| Dec 31, 2023 | 1.12B | 103.86M | 10.18% |
| Dec 31, 2022 | 1.02B | -946.25M | -48.12% |
| Dec 31, 2021 | 1.97B | 1.43B | 264.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 16.21B |
| GeneOne Life Science | 12.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.60B |
| MedPacto | 4.99B |